Vir Biotechnology, Inc. (VIR) shares are soaring 5.03% in intraday trading on Tuesday, buoyed by positive analyst ratings from major financial institutions. The biotechnology company's stock is experiencing significant upward momentum as investors react to the latest Wall Street assessments.

Morgan Stanley has reiterated its Buy rating on Vir Biotechnology, setting a price target of $20.00. This bullish stance from a leading investment bank suggests strong confidence in the company's future prospects. Additionally, TD Cowen has also maintained its Buy rating on VIR, further reinforcing the positive sentiment surrounding the stock.

These optimistic analyst views come at a crucial time for Vir Biotechnology, potentially indicating the market's growing recognition of the company's value proposition in the competitive biotech sector. As investors digest these recommendations, the stock's surge reflects increased buying interest and possibly renewed confidence in Vir's pipeline and strategic direction.